Cytokinetics (CYTK) Net Income towards Common Stockholders: 2009-2025
Historic Net Income towards Common Stockholders for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -$178.1 million.
- Cytokinetics' Net Income towards Common Stockholders fell 18.95% to -$178.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$602.1 million, marking a year-over-year decrease of 7.41%. This contributed to the annual value of -$573.9 million for FY2024, which is 9.43% down from last year.
- According to the latest figures from Q3 2025, Cytokinetics' Net Income towards Common Stockholders is -$178.1 million, which was down 47.96% from -$120.4 million recorded in Q2 2025.
- In the past 5 years, Cytokinetics' Net Income towards Common Stockholders registered a high of -$13.7 million during Q2 2022, and its lowest value of -$178.1 million during Q3 2025.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$134.6 million (2023), whereas its average is -$141.1 million.
- In the last 5 years, Cytokinetics' Net Income towards Common Stockholders plummeted by 6,173.01% in 2021 and then soared by 76.76% in 2022.
- Over the past 5 years, Cytokinetics' Net Income towards Common Stockholders (Quarterly) stood at -$25.9 million in 2021, then crashed by 417.27% to -$134.1 million in 2022, then declined by 0.37% to -$134.6 million in 2023, then decreased by 9.95% to -$148.0 million in 2024, then declined by 18.95% to -$178.1 million in 2025.
- Its last three reported values are -$178.1 million in Q3 2025, -$120.4 million for Q2 2025, and -$155.6 million during Q1 2025.